As of 2025-03-19, the EV/EBITDA ratio of 10X Genomics Inc (TXG) is -5.95. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXG's latest enterprise value is 941.31 mil USD. TXG's TTM EBITDA according to its financial statements is -158.16 mil USD. Dividing these 2 quantities gives us the above TXG EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.8x - 18.8x | 16.6x |
| Forward P/E multiples | 19.7x - 20.5x | 20.5x |
| Fair Price | (22.72) - (21.55) | (21.18) |
| Upside | -316.1% - -305.1% | -301.5% |
| Date | EV/EBITDA |
| 2025-03-05 | -6.28 |
| 2025-03-04 | -5.96 |
| 2025-03-03 | -5.44 |
| 2025-02-28 | -6.09 |
| 2025-02-27 | -6.16 |
| 2025-02-26 | -6.83 |
| 2025-02-25 | -6.42 |
| 2025-02-24 | -6.55 |
| 2025-02-21 | -6.25 |
| 2025-02-20 | -6.76 |
| 2025-02-19 | -7.18 |
| 2025-02-18 | -7.16 |
| 2025-02-14 | -7.35 |
| 2025-02-13 | -7.06 |
| 2025-02-12 | -7.10 |
| 2025-02-11 | -6.96 |
| 2025-02-10 | -7.15 |
| 2025-02-07 | -8.84 |
| 2025-02-06 | -9.15 |
| 2025-02-05 | -9.19 |
| 2025-02-04 | -8.97 |
| 2025-02-03 | -9.00 |
| 2025-01-31 | -9.42 |
| 2025-01-30 | -9.49 |
| 2025-01-29 | -9.30 |
| 2025-01-28 | -9.30 |
| 2025-01-27 | -9.31 |
| 2025-01-24 | -9.28 |
| 2025-01-23 | -9.35 |
| 2025-01-22 | -10.44 |
| 2025-01-21 | -10.32 |
| 2025-01-17 | -9.49 |
| 2025-01-16 | -9.49 |
| 2025-01-15 | -9.41 |
| 2025-01-14 | -9.76 |
| 2025-01-13 | -9.97 |
| 2025-01-10 | -9.87 |
| 2025-01-08 | -10.07 |
| 2025-01-07 | -9.83 |
| 2025-01-06 | -10.13 |
| 2025-01-03 | -9.89 |
| 2025-01-02 | -8.80 |
| 2024-12-31 | -8.93 |
| 2024-12-30 | -8.92 |
| 2024-12-27 | -9.11 |
| 2024-12-26 | -9.17 |
| 2024-12-24 | -9.17 |
| 2024-12-23 | -9.21 |
| 2024-12-20 | -8.68 |
| 2024-12-19 | -8.35 |